AGW0 Stock Chart & Stats
€0.20
<€0.01(1.49%)
―
--
Day’s Range― - ―
52-Week Range€0.10 - €0.43
Previous CloseN/A
VolumeN/A
Average Volume (3M)66.00
Market Cap
€1.83M
Enterprise Value€3.70M
Total Cash (Recent Filing)€210.03K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.61
Next Earnings
Dec 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding8,923,237
10 Day Avg. Volume0
30 Day Avg. Volume66
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.77
Price to Sales (P/S)0.00
P/FCF Ratio-1.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.18
Revenue Forecast (FY)€29.02M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetNo debt reduces interest expense and near-term repayment pressure, preserving financial flexibility while the company develops its VR healthcare and wellness offerings. This provides a stronger base for funding operations than a similarly loss-making business carrying material leverage.
Narrowing Net LossesThe substantial reduction in annual net losses indicates progress toward better cost discipline, even though profitability remains negative. If this improvement continues, it could extend the company’s funding runway and reduce the scale of future financing required to reach commercial revenue.
Improving Cash BurnLower free-cash-flow burn is a constructive operating trend because it suggests the company is consuming capital more slowly than in prior periods. Continued improvement could make its VR healthcare development strategy more sustainable while reducing dependence on frequent external funding.
Bears Say
No Demonstrated Revenue BaseZero reported revenue means the business has not yet demonstrated commercial traction or a repeatable monetization engine for its VR applications. Without revenue scale, future growth remains dependent on converting healthcare and wellness offerings into paying demand.
Persistent Negative Cash FlowPersistent operating and free-cash-flow deficits show that the company is not self-funding its activities. Until revenue scale or materially lower expenses change that position, external capital is likely to remain important, limiting financial flexibility and increasing funding risk.
Ongoing Equity Pressure And Negative ReturnsNegative returns on equity indicate that invested capital is not currently generating positive returns, while the pressured equity trend reflects ongoing value-erosion risk if losses persist. This weak capital efficiency can constrain the company’s ability to build durable shareholder value.
Grey Matters Health News
AGW0 FAQ
What was Grey Matters Health’s price range in the past 12 months?
Grey Matters Health lowest stock price was €0.10 and its highest was €0.43 in the past 12 months.
What is Grey Matters Health’s market cap?
Grey Matters Health’s market cap is €1.83M.
When is Grey Matters Health’s upcoming earnings report date?
Grey Matters Health’s upcoming earnings report date is Dec 18, 2026 which is in 49 days.
How were Grey Matters Health’s earnings last quarter?
Grey Matters Health released its earnings results on Jul 29, 2026. The company reported -€0.083 earnings per share for the quarter.
Is Grey Matters Health overvalued?
According to Wall Street analysts Grey Matters Health’s price is currently Undervalued.
Does Grey Matters Health pay dividends?
Grey Matters Health does not currently pay dividends.
What is Grey Matters Health’s EPS estimate?
Grey Matters Health’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Grey Matters Health have?
Grey Matters Health has 8,923,237 shares outstanding.
What happened to Grey Matters Health’s price movement after its last earnings report?
Grey Matters Health reported an EPS of -€0.083 in its last earnings report. Following the earnings report the stock price went down -4.484%.
Which hedge fund is a major shareholder of Grey Matters Health?
Currently, no hedge funds are holding shares in DE:AGW0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Grey Matters Health
Grey Matters Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of strokes and traumatic brain injuries. The company was formerly known as Algernon Health Inc. and changed its name to Grey Matters Health Inc. in April 2026. Algernon Health Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Technical Analysis
―
Rakovina Therapeutics Inc
―
Universal Ibogaine Inc
―
Mindbio Therapeutics Corp.
―
Neural Therapeutics Inc.
―